Management of relapsing-remitting multiple sclerosis: Diagnosis and treatment guidelines

European Journal of Neurology

Volumn 6, Issue SUPPL. 1, 1999, Pages

  Paty, Donald W ^a   Hartung, Hans Peter ^a   Ebers, George C ^a   Soelberg Sørensen, Per ^a   Abramsky, Oded ^a   Kesselring, Jürg ^a   Delwel, Gepke O ^a  

^a Lewin Group   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON; INTERFERON BETA SERINE; RECOMBINANT BETA INTERFERON;

ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION;

EID: 0033058691     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (131)

1. Abramsky O, Teitelbaum D, Arnon R (1977). Effect of a synthetic polypeptide (copolymer 1) on patients with multiple sclerosis and with acute disseminated encephalomyclitis. J Neurol Sci 31:433-438.
2. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, et al. (1998). Intravenous immunoglobulin treatment in multiple sclerosis. Effects on relapses. Neurology 50:398-402.
3. Alam J, McAllister A, Scaramucci J, Jones W, Rogge M (1997). Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFNβ-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration. Clin Drug Invest 14:35-43.
4. Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, et al. (1994) Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 57:897-902.
5. Antel J, Birnbaum G, Hartung HP (1998). Clinical neuroimmunology. London: Blackwell Science.
6. Arnason BGW, Dayal A, Qu ZX, Jensen MA, Gene K, Reder AT (1996). Mechanisms of action of interferon-β in multiple sclerosis. Springer Semin Immunopathol 18:125-148.
7. Arnon R (1996). The development of Cop 1 (Copaxone®), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunol Lett 50:1-15.
8. Arnon R, Teitelbaum D, Sela M (1989). Suppression of experimental allergic encephalomyelitis by COP1-relevance to multiple sclerosis. Isr J Med Sci 25:686-689.
9. Asbury AK, Herndon RM, McFarland HF, McDonald WI, McIlroy WJ, Paty DW, et al. (1987). National multiple sclerosis society working group on neuroimaging for the medical advisory board. Neuroradiology 29:119.
10. Audet AM, Greenfield S, Field M (1990). Medical practice guidelines: current activities and future directions. Ann Intern Med 113:709-714.
11. Barkhof F, Scheltens P, Frequin S, Nauta J, Tas MW, Valk J, Hommes OR (1992). Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging versus clinical findings in determining disease activity. A J R 159:1041-1047.
12. Barnes MP, Bateman DE, Cleland PG, Dick DJ, Walls TJ, Newman PK, et al. (1985). Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 48:157-159.
13. Bastianello S, Pozzilli C, Bernardi S, Bozzao L, Fantozzi LM, Buttinelli C, Fieschi C (1990). Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology 49:591-595.
14. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH (1993). The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. New Engl J Med 326:581-588.
15. Blumhardt LD, Paty DW, Hughes RAC, Weinshenker B (1998). Dosage effect of interferon β-1a (Rebif®) in preventing relapses and progression of disability in relapsing-remitting multiple scleropsis with baseline >3.5. J Neurol 243:371.
16. British and Dutch Multiple Sclerosis Azathioprine Trial Group (1988). Double-masked trial of azathioprine in multiple sclerosis. Lancet 2:179-183.
17. Brod SA, Lindsey JW, Wolinsky JS (1996). Multiple sclerosis: clinical presentation, diagnosis and treatment. Am Fam Physician 54:1301-1311.
18. Chiappa KH (1988). Use of evoked potentials for diagnosis of multiple sclerosis. Neurol Clin 6:861-880.
19. Cirelli R, Herne K, Tyring SK (1996). Interferons. An overview of their pharmacology. Clin Immunother 5(suppl 1):22-30.
20. Clark W (1996). Therapeutic advances: beta-interferon for multiple sclerosis. J Clin Pharm Ther 21:195-199.
21. Confravreux C (1994). Establishment and use of the multiple sclerosis register - EDMUS. Ann Neurol 36:S136-S139.
22. Confravreux C, Compston DAS, Hommes OR, McDonald WI, Thompson AJ (1992). EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 55:671-676.
23. Cook SD, Troiano R, Rohowsky-Kochin C, Jotkowitz A, Bielory L, Mehta PD, et al. (1992). Intravenous gamma globulin in progressive MS. Acta Neurol Scand 86:171-175.
24. Drislane FW (1994). Use of evoked potentials in the diagnosis and follow-up of multiple sclerosis. Clin Neurosci 2:196-201.
25. Durelli L, Bongioanni MR, Ferrero B, Oggero A, Marzano A, Rizetto M (1998). Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology 50:570-571.
26. Ebers GC (1996). Genetic epidemiology of multiple sclerosis. Curr Opin Neurol 9:155-158.
27. Ebers GC, Vinuela FV, Feasby T, Bass B (1984). Multifocal CT enhancement in MS. Neurology 34:341-346.
28. Ebers GC, Oger J, Paty DW and the PRISMS Study Group (1997). Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis. Ann Neurol 42:986 [abstract].
29. Eddy DM (1990). Practice policies: where do they come from? J Am Med Assoc 263:1265, 1269, 1272, 1275.
30. European Neurology Society (1998). Betaferon SP Trial, Nice, June.
31. European Study Group on Interferon β-1b in Secondary Progressive MS (1998). Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497.
32. Farrar M, Schreiber RD (1993). The molecular cell biology of interferon-γ and its receptor. Annn Rev Immunol 11:571-611.
33. Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkom K, Hörner S, Lechner H (1988). Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 38:1822-1825.
34. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B for the Austrian Immunoglobulin in Multiple Sclerosis Study Group (1997a). Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian immunoglobulin in MS study. Mult Scler 3:137-141.
35. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, for the Austrian Immunoglobulin in Multiple Sclerosis Study Group (1997b). Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 349:589-593.
36. Filippi M, Miller DH (1996). Magnetic resonance imaging in the differential diagnosis and monitoring of the treatment of multiple sclerosis. Curr Opin Neurol 9:178-186.
37. Francis GS, Arnaoutelis R, Antel JP (1994). Lack of efficiency of IVIgG in multiple sclerosis. Neurology 44(suppl 2):A357.
38. Francis GS, Freedman MS, Antel JF (1998). Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Mult Scler 3:370-376.
39. Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PL, et al. (1989). Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine. J Natl Cancer Inst 81:1061-1068.
40. Goodkin DE, Hertsgaard D, Rudick RA (1989). Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 46:1107-1112.
41. Hall GL, Compston A, Scolding NJ (1997). Beta-interferon and multiple sclerosis. TINS 20:63-67.
42. Hawkins MJ, Krown SE, Borden EC, Krim M, Real FX, Edwards BS, et al. (1984). American cancer society phase I trial of naturally produced beta-interferon. Cancer Res 44:5934-5938.
43. Herndon RM, Brooks B (1985). Misdiagnosis of multiple sclerosis. Semin Neurol 5:94-98.
44. IFMSS (International Federation of Multiple Sclerosis Societies) (1985). Minimal Record of Disability for Multiple Sclerosis. New York: National Multiple Sclerosis Society of the US.
45. IFNB Multiple Sclerosis Study Group (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661.
46. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995). Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 45:1277-1285,
47. Jacobs L, O'Malley J, Freeman A, Ekes R (1981). Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 214:1026-1028.
48. Jacobs L, O'Malley J, Freeman A, Ekes R (1982). Intrathecal interferon in multiple sclerosis. Arch Neurol 39:609-615.
49. Jacobs L, O'Malley JA, Freeman A, Ekes R, Reese PA (1985). Intrathecal Interferon in the treatment of multiple sclerosis: patient follow-up. Arch Neurol 42:841-847.
50. Jacobs LD, Cookfair DL, Rudick RA, Herndon R, Richert JR, Salazar AM, et al. and the Multiple Sclerosis Collaborative Research Group (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294,
51. Johnson KP (1997). The historical development of interferons as multiple sclerosis therapies. J Mol Med 75:89-91.
52. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. and the Copolymer 1 Multiple Sclerosis Study Group (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268-1276.
53. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. and the Copolymer 1 Multiple Sclerosis Study Group (1998). Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50:701-708.
54. Katz J, Taubenberger J, Raine C, et al. (1990). Gadolinium-enhanced lesion on magnetic resonance imaging: neuropathological findings. Ann Neurol 28:243.
55. Kidd D, Thorpe JW, Thompson AJ, Kendall BE, Moseley IF, MacManus DG, et al. (1993). Spinal cord MRI using multi-array coils and fast-spin echo. II. Findings in multiple sclerosis. Neurology 43:2632-2637.
56. Kurtzke JF (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452.
57. Lenercept MS Study Group and The UBC MS/MRI Analysis Group (1998). Tnf neutralization induces an increase in relapses in patients with multiple sclerosis. J Clin Neurol Sci (suppl 1):S31.
58. Liberati AM, Horisberger MA, Palmisano L, Astolfi S, Nastari A, Mechati S, et al. (1992). Double-blind randomised phase I study on the clinical tolerance and biological effects of natural and recombinant human interferon-β. J Interferon Res 12:329-336.
59. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS (1996). Management of patients receiving interferon beta-1b for multiple sclerosis. Report of a consensus conference. Neurology 46:12-18.
60. Lublin FD, Reingold SC, and the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis (1997). Guidelines for clinical trials of new therapeutic agents in multiple sclerosis. Relations between study investigators, advisors, and sponsors. Neurology 48:572-574.
61. Lucchinetti CF, Brück W, Rodriquez M, Lassmann (1996). Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 6:259-274.
62. Martin R, Hohlfeld R (1996). Current immunotherapy of multiple sclerosis. A review of clinical experience. Clin Immunother 5(suppl 1):12-21.
63. Matthews WB (1985). Differential diagnosis. In Matthews WB, Acheson ED, Batchelor JR, et al. (editors). McAlpines's multiple sclerosis. New York: Churchill Livingstone. pp. 146-166.
64. Mickey MR, Ellison GW, Myers LW (1984). An illness severity score for multiple sclerosis. Neurology 34:1343-1347.
65. Miller DH, Rudge P, Johnson G, Kendall BE, MacManus DG, Moseley IF, et al. (1988). Serial gadolinium enhanced magnetic resonance imaging in monitoring the treatment of multiple sclerosis. Brain 111:927-939.
66. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ (1991). Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J. Neurol Neurosurg Psychiatry 54:683-688.
67. Miller DH, Thompson AJ, Morrissey SP, MacManus DG, Moore SG, Kendall BE, et al. (1992). High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J. Neurol Neurusurg Psychiatry 55:450-453.
68. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, et al. (1996). Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 39:6-16.
69. Miller DH, Kesselring J, McDonald WI, Paty DW, Thompson AJ (1997). Magnetic resonance in multiple sclerosis. Cambridge: Cambridge University Press.
70. Munafo A, Rothuizen L, Spertini F, Trinchard I, Buclin T, Biollaz, J, et al. (1997). Pharmacodynamic response to INF β-1a administered subcutaneously once a week (QW) or three times a week (TIW) over 1 month. Mult Scler 3:226.
71. Munafo A, Trinchard-Lugan I, Nguyen TXQ, Buraglio M (1998). Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1 a after intramuscular and subcutaneous administration. Eur J Neurol 5:187-193.
72. Neuteboom B, Fava L, Maraschin R, Eshkol A, Hardy K, Fumero S, Ythier A (1997). Pharmacological studies with recombinant human interferon beta-1a (Rebif®): control of TNF alpha secretion. Presented at the 7th meeting of the European Neurological Society, 14-18 June 1997, Rhodes, Greece.
73. Offenbacher H, Fazckas F, Schmidt R, Freidl W, Flooh E, Payer F, Lechner H (1993). Assessment of MRT criteria for a diagnosis of MS. Neurology 43:905-909.
74. Paty DW (1992). Magnetic resonance imaging in the diagnosis and follow-up of patients with multiple sclerosis. Ital J Neurol Sci (suppl 2):125-131.
75. Paty DW (1993). Magnetic resonance in multiple sclerosis. Curr Opin Neurol Neurosurg 6:202-208.
76. Paty DW (1997). Interferon beta 1a (Rebif) in the treatment of relapsing-remitting multiple sclerosis: the MRI results of a large multicentre study. PRISMS Rebif Study Group. ECTRIMS, Istanbul, 3-5 November 1997.
77. Paty DW, Ebers GC (1998). Multiple sclerosis. Philadelphia: F.A. Davis Company.
78. Paty DW, Li DKB (1998). Diagnosis of multiple sclerosis 1998: do we need new diagnostic criteria? In Siva et al. (editors). Frontiers in multiple sclerosis. Vol. 2. London: Martin Dunitz. pp. 47-50.
79. Paty DW, Oger JJF, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, et al. (1988). MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38:180-185.
80. Paty DW, McFarlin DE, McDonald WI (1991). Magnetic resonance imaging and laboratory aids in the diagnosis of multiple sclerosis. Ann Neurol 29:3-5.
81. Paty DW, Li DKB, UBC MS/MRI Study Group and IFNB Multiple Sclerosis tudy Group (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of u multicenter, randomised, double-blind, placebo-controlled trial. Neurology 43:662-667.
82. Paty DW, Studey D, Redekop K, Lublin F (1994). MS COSTAR: a computerised patient record adapted for clinical purposes. Ann Neurol 36:S134-S135.
83. Paty DW, Goodkin D, Thompson A, Rice G (1996). Guidelines for physicians with patients on TFNβ-1b: the use of an assay for neutralising antibodies (NAB). Neurology 47:865-866.
84. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. (1983). New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231.
85. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group (1998). Randomised double-blind placebo controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504.
86. Raine CS (1990). Multiple sclerosis: immunopathologic mechanisms in the progression and resolution of inflammatory demyelination. In Waksman BH (editor). Immunologic mechanisms in neurologic and psychiatric disease. New York: Raven Press. pp.37-54.
87. Raine CS (1991). Multiple sclerosis: a pivotal role for the T cell in lesion development. Neuropathol Appl Neurobiol 17:265-274.
88. Raine CS (1994). The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 36:S61-S72.
89. Raine CS, McFarland HF, Tourtelotte WW (1997). Multiple sclerosis - clinical and pathological basis. London: Chapman & Hall Medical.
90. Ravnborg M, Liguori R, Christiansen P, Larsson H, Soelberg Sörensen P (1992). The diagnostic reliability of magnetically evoked motor potentials in multiple sclerosis. Neurology 42:1296-1301.
91. Reder AT (1996). Clinical pharmacology of interferon beta-1b and its potential role in multiple sclerosis. Clin Immunother 5(suppl 1):31-40.
92. Reder AT, Thapar M, Jensen MA (1994). A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis: implications for treatment of inflammatory brain disease. Neurology 44:2289-2294.
93. Report of the Quality Standards Subcommittee of the American Academy of Neurology (1994). Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 44:1537-1540.
94. Rolak LA (1996). The diagnosis of multiple sclerosis. Neurol Clin 14:27-43.
95. Rudick RA, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, et al. (1996a). Clinical outcomes assessment in multiple sclerosis. Ann Neurol 40:469-479.
96. Rudick RA, Ransohoff RM, Peppler R, VanderBrug Medendorp S, Lehman P, Alam J (1996b). Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 40:618-627.
97. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM (1997). Management of multiple sclerosis. New Engl J Med 337:1604-1611.
98. Rudick RA, Simonian NA, Alum JA, Campion M, Scaramucci JO, Jones W, et al. and the Multiple Sclerosis Collaborative Research Group (1998). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50:1266-1272.
99. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, et al. (1998). Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15:641-649.
100. Sadovnick AD, Ebers GC (1993). Epidemiology of multiple sclerosis: a critical overview. Can J Neural Sci 20:17-29.
101. Sadovnick AD, Ebers GC, Wilson RW, Paty DW (1992). Life expectancy in patients attending multiple sclerosis clinics. Neurology 42:991-994.
102. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A (1996). Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J Interferon Cytokine Res 16:759-764.
103. Schumacher GA, Beebe GW, Kibler RF, Kurlant LT, Kurtzke JF, McDowell F, et al. (1965). Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Med 122:552-568.
104. Sharrack B, Hughes RAC (1996). Clinical scales for multiple sclerosis. J Neurol Sci 135:1-9.
105. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, et al. and the Multiple Sclerosis Collaborative Research Group (1998). Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol 43:79-87.
106. Sipe JC, Knobler RL, Braheny SL, Rice GPA, Panitch HS, Oldstone MBA (1984). A neurological rating scale (NRS) for use in multiple sclerosis. Neurology 34:1368-1372.
107. Sorensen PS (1996). Intravenous Immunoglobulin G therapy: effects of aqute and chronic treatment in multiple sclerosis. Mult Scler 1:349-352.
108. Sorensen PS, Wanscher B, Schreiber K, Blinkenberg M, Jensen CV, Ravnborg M (1997). A double-blind, crossover trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results. Mult Scler 3:145-148.
109. Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, et al. (1998). Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50:1273-1281.
110. Standards of Healthcare for People with MS (1997). A joint publication by the Multiple Sclerosis Society of Great Britain and Northern Ireland and the Neurohabilitation and Therapy Services Directorate of the National Hospital for Neurology and Neurosurgery.
111. Stangel M, Hartung HP, Marx P, Gold R (1997). Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol 20:385-393.
112. Stangel M, Hartung HP, Marx P, Gold R (1998). Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 153:203-214.
113. Steinman L (1996). Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85:299-302.
114. Swain SE (1996). Multiple sclerosis: Primary health care implications. Nurse Pract 21:40, 43, 47-50.
115. Swanson JW (1989). Multiple sclerosis: update in diagnosis and review of prognostic factors. Mayo Clin Proc 64:577-586.
116. Tas MW, Barkhof F, van Walderveen MAA, Polman CH, Hommes OR, Valk J (1995). The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis. Am J Neuroradiol 16:259-264.
117. Teitelbaum D, Meshorer A, Hirschfield T, Arnon R, Sela M (1971). Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1:242-248.
118. Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M (1973): Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol 3:273-279.
119. Teitelbaum D, Arnon R, Sela M (1997). Copolymer 1: from basic research to clinical application. Cell Mol Life Sci 53:24-28.
120. Tenser RB, Hay KA, Aberg JA (1993). Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets. Arch Neurol 50:417-420.
121. Thompson AJ (1996). Clinical review of multiple sclerosis. Clin Immunother 5(suppl 1):1-11.
122. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M, et al. (1997). Primary progressive multiple sclerosis. Brain 120:1085-1096.
123. Thorpe JW, Kidd D, Moseley IF, Kendall BE, Thompson AJ. MacManus DG, et al. (1996). Serial gadolinium enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 46:373-378.
124. Tourtellotte WW, Baumhefner RW, Syndulko K, Shapahak P, Osborne M, Rubinshtein G, et al. (1988). The long march of the cerebrospinal fluid profile indicative of clinical definitive multiple sclerosis; and still marching. J Neuroimmunol 20:217-227.
125. Truyen L (1992). Magnetic resonance imaging in multiple sclerosis. A review. Acta Neurol Belg 94:98-102.
126. Weinshenker BG (1995). The natural history of multiple sclerosis. Neurol Clin 13:119-146.
127. Weinstock-Guttman B, Cohen JA (1996). Newer versus older treaments for relapsing remitting multiple sclerosis. Drug Saf 14:121-130.
128. Woolf SH (1992). Practice guidelines, a new reality in medicine. II. Methods of developing guidelines. Arch Intern Med 152:946-952.
129. Wray SH (1995). Optic neuritis: guidelines. Curr Opin Neurol 8:72-76.
130. Young IR, Hall AS, Pallis CA, Legg NJ, Bydder GM, Steiner RE (1981). Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet ii:1063-1066.
131. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K, et al. (1991). Overview of azathioprine treatment in multiple sclerosis. Lancet 338:1051-1055.